Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Integral Diagnostics Ltd. (AU:IDX – Research Report), Biophytis SA (DE:6XB – Research Report) and Merck KGaA (GB:0O14 – Research Report).
Integral Diagnostics Ltd. (AU:IDX)
Ord Minnett analyst Ord Minnett downgraded Integral Diagnostics Ltd. to Hold yesterday and set a price target of A$3.60. The company’s shares closed last Friday at A$3.44.
Integral Diagnostics Ltd. has an analyst consensus of Moderate Buy, with a price target consensus of A$3.10.
See Insiders’ Hot Stocks on TipRanks >>
Biophytis SA (DE:6XB)
Kepler Capital analyst Nicolas Pauillac maintained a Hold rating on Biophytis SA on May 9 and set a price target of EUR0.04. The company’s shares closed yesterday at EUR0.02.
According to TipRanks.com, Pauillac is ranked #3258 out of 8374 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Biophytis SA with an EUR0.04 average price target.
Merck KGaA (GB:0O14)
UBS analyst Michael Leuchten maintained a Buy rating on Merck KGaA yesterday and set a price target of EUR210.00. The company’s shares closed yesterday at EUR165.05.
According to TipRanks.com, Leuchten is ranked #3282 out of 8374 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Merck KGaA with an EUR210.20 average price target, representing a 30.8% upside. In a report issued on April 28, Kepler Capital also maintained a Buy rating on the stock with a EUR209.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
